Allgemeines
Studien
| Studie | Jahr | Patienten | Alter | % T-ALL | 5a-ZNS-Rez | 5a-RFS | 5a-OS |
| AIEOP-95 (1) | 1995-2000 | 1.743 | 0-18 | 11 | 1,2 +- 0,3 | 75,9 +- 1,0 | 85,5 +- 0,8 |
| BFM-95 (2) | 1995-1999 | 2.169 | 0-18 | 13 | 1,8 +- 0,3 | 79,6 +- 0,9 | 87,0 +- 0,7 |
| CoALL-97 (3) | 1997-2003 | 667 | 1-18 | 14 | 4,0 +- 0,8 | 76,7 +- 1,7 | 85,4 +- 1,4 |
| COG (4) | 2000-2005 | 7.153 | 0-21 | 7 | NA | NA | 90,4 +- 0,5 |
| DCOG-9 (5) | 1997-2004 | 859 | 1-18 | 11 | 2,6 +- 0,6 | 80,6 +- 1,4 | 86,4 +- 1,2 |
| DFCI00-01 (6) | 2000-2004 | 492 | 1-18 | 11 | NA | 80,0 +- 2 | 91 +- 1 |
| EORTC-CLG (7) | 1998-2008 | 1.947 | 1-18 | 15,2 | 1,7 +- 0,3 | 82,7 +- 0,9 | 89,7 +- 0,7 |
| IC-BFM 2002 (8) | 2002-2007 | 5.060 | 1-18 | 13,3 | 1,9 +- 0,1 | 74 +- 1 | 82 +- 1 |
| JCCLSG ALL 2000 (9) | 2000-2004 | 305 | 1-15 | 9,8 | 0,9 +- 0,1 | 79,7 +- 2,4 | 89,2 +- 1,8 |
| Ma-Spore ALL 2003 (10) | 2002-2011 | 556 | 0-18 | 8,8 | 1,4 | 80,6 +- 3,5 | 89,2 +- 2,7 |
| MRC UKALL 2003 (11) | 2003-2011 | 3.126 | 1-25 | 12 | 1,9 +- 0,6 | 87,3 +- 1,4 | 91,6 +- 1,2 |
| NOPHO-2000 (12) | 2002-2007 | 1.023 | 1-15 | 11 | 2,7 +- 0,6 | 79,4 +- 1,5 | 89,1 +- 1,1 |
| SJCRH XV (13) | 2000-2007 | 498 | 1-18 | 15 | 2,7 +- 0,8 | 87,3 +- 2,9 | 93,5 +- 1,9 |
| TPOG (14) | 1999-2010 | 152 | 0-18 | 7,2 | 1,4 +- 1,0 | 84,2 +- 3,0 | 90,2 +- 2,4 |
Quellen
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia.
Leukemia 2010;24:255-264
2.) Möricke A, Zimmermann M, Reiter A, et al:
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.
Leukemia 2010;24:265-284
3.) Escherich G, Horstmann MA, Zimmermann M, et al:
Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): Long-term results of trials 82, 85, 89, 92 and 97.
Leukemia 2010;24:298-308
4.) Hunger SP, Lu X, Devidas M, et al:
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the Children’s Oncology Group.
J Clin Oncol 2012;30:1663-1669
5.) Veerman AJ, Kamps WA, van den Berg H, et al:
Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: Results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
Lancet Oncol 2009;10:957-966
6.) Vrooman LM, Stevenson KE, Supko JG, et al:
Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: Re- sults from a randomized study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
J Clin Oncol 2013;31:1202-1210
7.) Domenech C, Suciu S, De Moerloose B, et al:
Dexamethasone (6 mg/m2/day) and prednisolone(60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial.
Haematologica 2014;99:1220-1227
8.) Stary J, Zimmermann M, Campbell M, et al:
Intensive chemotherapy for childhood acute lymphoblastic leukemia: Results of the randomized intercontinental trial ALL IC-BFM 2002.
J Clin Oncol 2014;32:174-184
9.) Yamaji K, Okamoto T, Yokota S, et al:
Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: A report from the Japanese Childhood Cancer and Leukemia Study Group.
Pediatr Blood Cancer 2010;55:1287-1295
10.) Yeoh AE, Ariffin H, Chai EL, et al:
Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: Results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
J Clin Oncol 2012;30:2384-2392
11.) Vora A, Goulden N, Mitchell C, et al:
Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial.
Lancet Oncol 2014;15:809-818
12.) Schmiegelow K, Forestier E, Hellebostad M, et al:
Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia.
Leukemia 2010;24:345-354
13.) Pui CH, Pei D, Campana D, et al:
A revised definition for cure of childhood acute lymphoblastic leukemia.
Leukemia 2014;28:2336-2343
14.) Liu HC, Yeh TC, Hou JY, et al:
Triple intrathecal therapy alone with omission of cranial radiation in children with acute lymphoblastic leukemia.
J Clin Oncol 2014;32:1825-1829
